Spero Therapeutics (SPRO) Competitors

Trevi Therapeutics (NASDAQ:TRVI) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.

Do institutionals and insiders believe in TRVI or SPRO?

76.3% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 27.3% of Spero Therapeutics shares are owned by institutional investors. 27.5% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is TRVI or SPRO more profitable?

Trevi Therapeutics has a net margin of 0.00% compared to Trevi Therapeutics' net margin of -2.08%. Trevi Therapeutics' return on equity of 4.14% beat Spero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-27.16%	-24.53%
Spero Therapeutics	-2.08%	4.14%	2.33%

Which has better valuation and earnings, TRVI or SPRO?

Trevi Therapeutics has higher earnings, but lower revenue than Spero Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$29.15M	-$0.27	-4.30
Spero Therapeutics	$53.51M	1.28	-$46.42M	$0.01	129.00

Which has more risk & volatility, TRVI or SPRO?

Trevi Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Does the media prefer TRVI or SPRO?

In the previous week, Trevi Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Trevi Therapeutics and 0 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.58 beat Trevi Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Positive
Spero Therapeutics	Neutral

Does the MarketBeat Community favor TRVI or SPRO?

Spero Therapeutics received 123 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 68.88% of users gave Spero Therapeutics an outperform vote while only 59.68% of users gave Trevi Therapeutics an outperform vote.

Company	Underperform	Outperform
Trevi Therapeutics	Outperform Votes 74 59.68%	Underperform Votes 50 40.32%
Spero Therapeutics	Outperform Votes 197 68.88%	Underperform Votes 89 31.12%

Do analysts prefer TRVI or SPRO?

Trevi Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 503.45%. Spero Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 451.18%. Given Spero Therapeutics' higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Spero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Trevi Therapeutics and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.